Erythropoietin for critically ill trauma patients: A missed opportunity?

Journal of Trauma and Acute Care Surgery

Volumn 77, Issue 5, 2014, Pages 774-779

  Corwin, Howard L ^a   Napolitano, Lena M ^b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; CRITICAL ILLNESS; CRITICALLY ILL PATIENT; ERYTHROCYTE TRANSFUSION; HEMOGLOBIN DETERMINATION; HUMAN; INFLAMMATION; INJURY; MORTALITY; PRIORITY JOURNAL; REVIEW; VENOUS THROMBOEMBOLISM;

EID: 84925858573     PISSN: 21630755     EISSN: 21630763     Source Type: Journal    
DOI: 10.1097/TA.0000000000000442     Document Type: Review

References (38)

1. Nathan AB, Rivara FP, MacKenzie EJ, Maier RV, Wang J, Eglestir B, Scharfstein DO, Jurkovich GJ. The impact of an intensivist-model ICU on trauma-related mortality. Ann Surg. 2006; 244: 545-554.
2. Corwin HL, Gettinger A, Fabian T, May Addison Pearl RG, Heard S, An R, Bowers P, Burton P, Klausner MA, Corwin MJ. Efficacy and safety of epoetin alpha in the critically ill. N Engl J Med. 2007; 357: 965-976.
3. Corwin HL, Gettinger A, Rodriguez RM, et al. Efficacy of recombinant human erythropoietin in the critically ill patient: a randomized double blind placebo controlled trial. JAMA. 2002; 288: 2827-2835.
4. Napolitano LM, Fabian TC, Kelly KM, Bailey JA, Block EF, Langholff W, Enny C, Corwin HL. Improved survival of critically ill traumapatients treated with recombinant human erythropoietin. J Trauma. 2008; 65 (2): 285-299.
5. Corwin HL, Gettinger A, Pearl RG, Fink MP, Levy MM, Abraham E, MacIntyre NR, Shabot MM, Duh MS, Shapiro MJ. The CRIT Study: anemia and blood transfusion in the critically illVcurrent clinical practice in the United States. Crit Care Med. 2004; 32 (1): 39-52.
6. Shapiro MJ, Gettinger A, Corwin HL, Napolitano L, Levy M, Abraham E, Fink MP, MacIntyre N, Pearl RG, Shabot MM. Anemia and blood transfusion in trauma patients admitted to the intensive care unit. J Trauma. 2003; 55 (2): 269-273; discussion 273-274.
7. Rodriguez RM, Corwin HL, Gettinger A, Corwin MJ, Gubler D, Pearl RG. Nutritional deficiencies and blunted erythropoietin response as causes of the anemia of critical illness. J Crit Care. 2001; 16: 36-41.
8. Hobisch-Hagen P, Wiedermann F, Mayr A, Fries D, Jelkmann W, Fuchs D, Hasilbeder W, Mutz N, Klinger A, Schobersberger W. Blunted erythropoietic response to anemia in multiply traumatized patients. Crit Care Med. 2001; 29: 743-747.
9. Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood. 2003; 102 (3): 783-788.
10. Andrews NC. Anemia of inflammation: the cytokine-hepcidin link. J Clin Invest. 2004; 113 (9): 1251-1253.
11. Sihler KC, Raghavendran K, Westerman M, Ye W, Napolitano LM. Hepcidin in trauma: linking injury, inflammation, and anemia. J Trauma. 2010; 69 (4): 831-837.
12. Sasaki Y, Noguchi-Sasaki M, Yasuno H, Yorozu K, Shimonaka Y. Erythropoietin stimulation decreases hepcidin expression through hematopoietic activity on bone marrow cells in mice. Int J Hematol. 2012; 96 (6): 692-700.
13. De Domenico I, Zhang TY, Koening CL, Branch RW, London N, Lo E, Daynes RA, Kushner JP, Li D, Ward DM, et al. Hepcidin mediates transcriptional changes that modulate acute cytokine-induced inflammatory responses in mice. J Clin Invest. 2010; 120 (7): 2395-2405.
14. Maliken BD, Nelson JE, Kowdley KV. The hepcidin circuits act: balancing iron and inflammation. Hepatology. 2011; 53 (5): 1764-1766.
15. Kautz L, Jung G, Valore EV, Rivella S, Nemeth E, Ganz T. Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat Genet. 2014; 46 (7): 678-684.
16. Corwin HL, Gettinger A, Rodriguez RM, Pearl RG, Enny C, Colton T, Corwin MJ. Efficacy of recombinant human erythropoietin in the critically ill patient: a randomized double blind placebo controlled trial. Crit Care Med. 1999; 27: 2346-2350.
17. Silver M, Corwin MJ, Barzan A, Gettinger A, Corwin HL. Efficacy of recombinant human erythropoietin in the long term acute care patient: a randomized double blind placebo controlled trial. Crit Care Med. 2006; 34: 2310-2316.
18. Zarychanski R, Turgeon AF, McIntyre L, Fergusson DA. Erythropoietinreceptor agonists in critically ill patients: a meta-analysis of randomized controlled trials. CMAJ. 2007; 177: 725-734.
19. Luchette FA, Pasquale MD, Fabian TC, Langholff WK, Wolfson M. A randomized, double-blind, placebo-controlled study to assess the effect of recombinant human erythropoietin on functional outcomes in anemic, critically ill, trauma subjects: the long term trauma outcomes study. Am J Surg. 2012; 203: 508-516.
20. Sun X, Ioannidis JPA, Agoritsas T, Alba AC, Guyatt G. How to use subgroup analysis user's guide to the medical literature. JAMA. 2014; 311: 405-411.
21. Zhang Y, Wang L, Dey S, Alnaeeli M, Suresh S, Rogers H, Teng R, Noguchi CT. Erythropoietin action in stress response, tissue maintenance and metabolism. Int J Mol Sci. 2014; 15 (6): 10296-10333.
22. Noguchi CT,Wang L, Rogers HM, Teng R, Jia Y. Survival and proliferative roles of erythropoietin beyond the erythroid lineage. Expert Rev Mol Med. 2008; 10: e36.
23. Brines M, Cerami A. Erythropoietin-mediated tissue protection: reducing collateral damage from primary injury response. J Intern Med. 2008; 264: 405-432.
24. Hand CC, Brines M. Promises and pitfalls in erythropoietin-mediated tissue protection: are nonerythropoietic derivatives a way forward. J Invest Med. 2011; 59: 1073-1082.
25. Ogunshola OO, Bogdanova AY. Epo and non-hematopoietic cells: what do we know? Methods Mol Biol. 2013; 982: 13-41.
26. Erbayraktar S, Yilmaz O, Gökmen N, Brines M. Erythropoietin is a multifunctional tissue-protective cytokine.CurrHematolRep. 2003; 2 (6): 465-470.
27. Arcasoy MO. The non-haematopoietic biological effects of erythropoietin. Br J Haematol. 2008; 141 (1): 14-31.
28. Patel NSA, Nandra KK, Thiemermann C. Bench-to bedside review: erythropoietin and its derivatives as therapies in critical care. Crit Care. 2012; 16: 229.
29. Vasileiou PV, Xanthos T, Barouxis D, Pantazopoulos C, Papalois AE, Lelovas P, Kotsilianou O, Pliatsika P, Kouskouni E, Iacovidou N. Erythropoietin administration facilitates return of spontaneous circulation and improves survival in a pig model of cardiac arrest. Am J Emerg Med. 2014; 32: 871-877.
30. Grmec S, Strnad M, Kupnik D, Sinkovic A, Gazmuri RJ. Erythropoietin facilitates the return of spontaneous circulation and survival in victims of out-of-hospital cardiac arrest. Resuscitation. 2009; 80 (6): 631-637.
31. Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, Zwahlen M, Clarke M, Weingart O, Kluge S, et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomized trials. Lancet. 2009; 373: 1532-1542.
32. Zhang Y, Thamer M, Kaufman JS, Cotter DJ, Hernan MA. High doses of epoetin do not lower the mortality and cardiovascular risk among elderly hemodialysis patients with diabetes. Kidney Int. 2011; 80: 663-669.
33. Mesgarpour B, Heidinger BH, Schwameis M, Kienbacher C, Walsh C, Schmitz S, Herkner H. Safety of off-label erythropoiesis stimulating agents in critically ill patients: a meta-analysis. Intensive Care Med. 2013; 39: 1896-1908.
34. Cook D, Crowther M. Targeting anemia with erythropoietin during critical illness. N Engl J Med. 2007; 357: 1037-1039.
35. Balas EA, Boren SA. Managing clinical knowledge for health care improvement. Yearb Med Inform. 2000; 65-70.
36. Zarychanski R, Houston DS. Anemia of chronic disease: a harmful disorder or an adaptive, beneficial response?. CMAJ. 2008: 179; 333-337.
37. Kautz L, Jung G, Valore EV, Rivella S, Nemeth E, Ganz T. Identification of erythroferrone as an erythroid regulator of iron metabolism. NAT GENET. 46: 678-684.
38. Noguchi CT,Wang L, Rogers HM, Teng R, Jia Y. Survival and proliferative roles of erythropoietin beyond the erythroid lineage. Expert Rev Mol Med. 2008; 10-e36.